《大行報告》瑞銀升默克藥廠(MRK.US)評級至「買入」 目標價上調至122美元
瑞銀發表報告指,將默克藥廠(MRK.US)評級由「中性」升至「買入」,目標價由117美元上調至122美元。上調評級反映了默克在Keytruda和Gardasil藥物推動下高於同行的增長,以及未被充分重視的催化劑。該行認為,隨著Keytruda和Gardasil在早期腫瘤適應症和在中國市場的滲透率不斷提高,市場對兩藥預期將持續增加。
瑞銀指,雖然Keytruda在2028年底專利到期應該會使估值出現折讓,但管理層正積極將現金流再投資於研發和潛在的價值提升併購,以抵銷有關影響。而多個管線項目推進是未來幾年公司業績擴張的關鍵。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.